The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Open accessAbstract
Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574
Active and Inactive Protein Kinases: Structural Basis for Regulation
Johnson, L. N., Noble, M. E. M., & Owen, D. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81092-2 · Cited by 1,403
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine
Tang, W., & Eisenbrand, G. (1992) · Springer eBooks · doi:10.1007/978-3-642-73739-8 · Cited by 992
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Chao, S.-H., & Price, D. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102306200 · Cited by 621
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
De Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine
Tang, W., & Eisenbrand, G. (1992) · Cited by 453
A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
Tong, L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., & Pargellis, C. A. (1997) · Nature Structural Biology · doi:10.1038/nsb0497-311 · Cited by 387
Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 335
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China
Xiao, Z., Hao, Y., Liu, B., & Qian, L. (2002) · Leukemia & Lymphoma · doi:10.1080/1042819021000006295 · Cited by 285
Corbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Progress in Cell Cycle Research
(1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7 · Cited by 237
Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233
Young, T. A., Delagoutte, B., Endrizzi, J. A., Falick, A. M., & Alber, T. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb897 · Cited by 229
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J. A., Gibson, A. E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb842 · Cited by 219
Self-citationHarper, J. W., & Adams, P. D. (2001) · Chemical Reviews · doi:10.1021/cr0001030 · Cited by 219
Structural Basis for Chk1 Inhibition by UCN-01
Zhao, B., Bower, M. J., McDevitt, P. J., Zhao, H., Davis, S. T., Johanson, K. O., Green, S. M., Concha, N. O., & Zhou, B.-B. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201233200 · Cited by 206
Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
Fitzgerald, C. E., Patel, S. B., Becker, J. W., Cameron, P. M., Zaller, D., Pikounis, V. B., O'Keefe, S. J., & Scapin, G. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb949 · Cited by 182
Protein Kinase Inhibitors as a Therapeutic Modality
Levitzki, A. (2003) · Accounts of Chemical Research · doi:10.1021/ar0201207 · Cited by 178
Kim, K. S., Kimball, S. D., Misra, R. N., Rawlins, D. B., Hunt, J. T., Xiao, H.-Y., Lu, S., Qian, L., Han, W.-C., Shan, W., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0201520 · Cited by 172
Takada, Y., & Aggarwal, B. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m304546200 · Cited by 169
Protein Kinase A in Complex with Rho-Kinase Inhibitors Y-27632, Fasudil, and H-1152P
Breitenlechner, C. B., Gaßel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R. A., & Bossemeyer, D. (2003) · Structure · doi:10.1016/j.str.2003.11.002 · Cited by 162
Schiering, N., Knapp, S., Marconi, M., Flocco, M. M., Cui, J., Perego, R., Rusconi, L., & Cristiani, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734128100 · Cited by 156
Komander, D., Kular, G. S., Jennifer, B. A. I. N., Elliott, M., Alessi, D. R., & van Aalten, D. M. F. (2003) · Biochemical Journal · doi:10.1042/bj20031119 · Cited by 126
Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site
Oikonomakos, N. G., Schnier, J. B., Zographos, S. E., Skamnaki, V. T., Tsitsanou, K. E., & Johnson, L. N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004485200 · Cited by 124
Self-citationH-Series Protein Kinase Inhibitors and Potential Clinical Applications
Ono-Saito, N., Niki, I., & Hidaka, H. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00070-9 · Cited by 108
Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer
Sridhar, S. S., & Shepherd, F. A. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00308-8 · Cited by 104
Structural aspects of protein kinase control—role of conformational flexibility
Engh, R. A., & Bossemeyer, D. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00180-8 · Cited by 101
Signal Transduction–Directed Cancer Treatments
Sausville, E. A., Elsayed, Y. A., Monga, M., & Kim, G. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135813 · Cited by 96
Lakkakorpi, P. T., Wesolowski, G. A., Zimolo, Z., Rodan, G. A., & Rodan, S. B. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3797 · Cited by 82
HER-Targeted Tyrosine-Kinase Inhibitors
Baselga, J. M., & Hammond, L. A. (2002) · Oncology · doi:10.1159/000066198 · Cited by 76
Targeting tumor cells by enhancing radiation sensitivity
McKenna, W. G., & Muschel, R. J. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10296 · Cited by 67
Johnson, L. N., Moliner, E. D., Brown, N. R., Song, H., Barford, D., Endicott, J., & Noble, M. E. M. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00181-x · Cited by 66
Self-citationWissner, A., Floyd, M. B., Rabindran, S. K., Nilakantan, R., Greenberger, L. M., Shen, R., Wang, Y., & Tsou, H. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00598-x · Cited by 65
Insights into Cyclin Groove Recognition
Kontopidis, G. A., Andrews, M. J. I., McInnes, C., Cowan, A., Powers, H., Innes, L., Plater, A., Griffiths, G., Paterson, D., Zheleva, D. I., et al. (2003) · Structure · doi:10.1016/j.str.2003.11.006 · Cited by 62
The Cyclin-Dependent Kinase (CDK) Inhibitor Flavopiridol Inhibits Glycogen Phosphorylase
Kaiser, A., Nishi, K., Gorin, F. A., Walsh, D. A., Bradbury, E. M., & Schnier, J. B. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2220 · Cited by 57
Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma
Gebbia, V., Mauceri, G., Fallica, G., Borsellino, N., Tirrito, M. L., Testa, A., Varvara, F., Colombo, A., & Ferrera, P. (2002) · Oncology · doi:10.1159/000065716 · Cited by 34
Research works printed but not linked: 9
- D. J. Pratt J. A. Endicott M. E. Noble Curr. Opin. Drug Discov. Dev. in press.
- J. Baselga, L. A. Hammond, Oncology63, (Suppl. 1), 6 (2002).
- F. J. Giles, Oncology (Huntington)16, 23 (2002).
- 10.1007/s11864-001-0070-0 · doi:10.1007/s11864-001-0070-0
- 10.1345/aph.1A162 · doi:10.1345/aph.1a162 · Paper page
- G. Shapiroet al., Proc. Am. Soc. Clin. Oncol.22, 199 (2003).
- 10.1021/ar0201198 · doi:10.1021/ar0201198
- B. Nagaret al., Cancer Res.62, 4236 (2002).
- 10.1016/j.str.2003.09.020 · doi:10.1016/j.str.2003.09.020
Cited by
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
GraphDTA: predicting drug–target binding affinity with graph neural networks
Nguyen, T., Le, H., Quinn, T. P., Nguyen, T., Le, T. D., & Venkatesh, S. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa921 · Cited by 1,220
Metadata
- Authors
- Noble, M. E. M., Endicott, J. A., & Johnson, L. N.
- Venue
- Science
- Published
- 2004-03-19
- Volume
- 303
- Issue
- 5665
- Pages
- 1800-1805
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2138072853
- Cited by
- 1,198
- References
- 67
- FWCI
- 30.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.